Nitrous oxide and iso¯urane have cerebral vasodilatory effects. The use of iso¯urane in neuroanaesthesia is widely accepted, whereas the use of nitrous oxide in neuroanaesthesia is still the subject of debate. In the present study, contrast-enhanced magnetic resonance (MR) perfusion measurement was used to compare the effects of 0.4 MAC nitrous oxide (n=9) and 0.4 MAC iso¯urane (n=9) on regional cerebral blood¯ow (rCBF), regional cerebral blood volume (rCBV) and regional mean transit time (rMTT) in spontaneously breathing human volunteers. Nitrous oxide increased rCBF and rCBV in supratentorial regions more than did iso¯urane. Iso¯urane, by contrast, increased rCBF and rCBV in basal ganglia more than did nitrous oxide. An increased rMTT was caused by a relatively greater increase in rCBV than in rCBF supratentorially by iso¯urane and infratentorially by nitrous oxide. In conclusion, nitrous oxide increases rCBF and rCBV predominantly in supratentorial grey matter, whereas iso¯urane increases rCBF and rCBV predominantly in infratentorial grey matter.
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Nitrous oxide has been used in anaesthesia for more than a century 1 because of its dose-dependent analgesic and anaesthetic properties. 2 The use of nitrous oxide in certain situations (e.g. intracranial surgery), however, is still the subject of debate as the drug is a potent cerebral vasodilator. 3 In combination with potent inhalational anaesthetics, e.g. iso¯urane, nitrous oxide is known to increase mean cerebral blood¯ow (CBF). 4 By contrast, iso¯urane, which has become the anaesthetic of choice for neuroanaesthesia, 5 was shown to decrease global CBF in a dose-dependent manner in animals. 6 A systematic study comparing nitrous oxide with iso¯urane for their regional effects on CBF and simultaneously on regional cerebral blood volume (rCBV) in humans has not yet been conducted.
The present study used contrast-enhanced magnetic resonance imaging (MRI) perfusion measurements to investigate the in¯uence of nitrous oxide and iso¯urane on regional cerebral blood¯ow (rCBF), rCBV and regional mean transit time (rMTT). rMTT was used to analyse changes in rCBV in relation to changes in rCBF.
Methods
After approval by the local university ethics committee and written informed consent, 20 right-handed, non-smoking male volunteers (ASA physical status I) with no history of drug or alcohol abuse underwent MRI measurement of contrast-enhanced cerebral perfusion on two consecutive days. For each volunteer, the order of measurements (e.g. control and test-drug measurement), which were separated by 24 h, was allocated randomly. The volunteers were then allocated randomly to receive either iso¯urane or nitrous oxide as the test drug.
Wearing a closely ®tting face-mask, the volunteers breathed to achieve normocarbia [end-tidal carbon dioxide concentration (E¢ CO MRI measurements were performed with a 1.5-tesla whole-body scanner (Magnetom Vision; Siemens, Erlangen, Germany) using a standard circular polarized head-coil. Single-shot echoplanar imaging (EPI) was performed with a repetition time of 2 s and an echo time of 64 ms. An acquisition matrix of 64Q128 (®eld of view 22Q22 cm, in-plane resolution 1.7Q3.4 mm) was used. The slice thickness was set to 5 mm (slice gap 1.25 mm) and 15 slices were measured simultaneously. A paramagnetic contrast agent gadolinium-diethylene triamine pentaacetic acid (Gd-DTPA, 0.1 mmol kg ±1 ) was injected into an antecubital vein at the rate of 9 ml s ±1 using an MRcompatible power injector (Spectris; Medrad, Pittsburgh, PA, USA). EPI scans (n=60) were performed at 2-s intervals to cover the entire passage of the contrast agent through the brain. Six scans (6/60 scans) taken before injection were used as the baseline.
rCBV and rCBF were calculated by a blinded investigator in regions of interest. In each subject, regions of interest were outlined freehand bilaterally in white and in grey matter (frontal, parietal, occipital, striatal and thalamic) on CBV maps (Fig. 1 ). Outlining regions of interest on corresponding anatomical T 2 -weighted scans is not possible as EPI T 2 *-weighted contrast-enhanced perfusion scans have a known geometric distortion. In order to check the regions of interest for correct anatomical position, they were copied into the EPI T 2 *-weighted scans acquired before contrast media application. The de®nition of regions produced in this way is reliable and reproducible and is not biased to high signal areas on the CBV maps. Furthermore, varying partial volume effects as a result of the inclusion of white and grey matter in regions allocated primarily to one category, which could account for some of the differences between the regions, were minimized. Corresponding regions of interest contained similar numbers of pixels.
The basic concept used to determine CBV and CBF was described by Ostergaard et al. 9±11 An improved gamma variate ®t was used to reduce underestimation of the arterial input function, which otherwise leads to overestimation of CBV and CBF values. 12 After correction for the density of brain tissue, 13 rCBF values are given in ml 100 g ±1 min ±1 and rCBV values in ml 100 g ±1 . MTT, which de®nes the average time that any particle of tracer, e.g. contrast medium, remains within the region of interest, 14 was calculated with the equation:
Values for rMTT are given in seconds. Responsiveness to verbal command, which was necessary once or twice in each volunteer in order to maintain normocapnia, was sustained during iso¯urane (n=9) and nitrous oxide (n=9) administration. The contrast-enhanced perfusion measurement was commenced only after verbal command had produced stable normocapnia, so that no Effects of nitrous oxide on CBF and CBV further verbal stimulation was needed during perfusion measurement.
Statistical analysis
Haemodynamic (heart rate, MAP) and respiratory (Sp O 2 , E¢ CO 2 , respiratory rate) variables were in¯uenced neither by iso¯urane nor by nitrous oxide.
rCBF
Iso¯urane increased occipital but not frontal or parietal grey matter rCBF ( Fig. 2A) , whereas nitrous oxide increased rCBF in all of these regions (Fig. 2B) . In the basal ganglia, except for the right hemispheric striatum, however, iso¯urane increased rCBF more than did nitrous oxide ( Fig. 3A and B) .
rCBV
Both iso¯urane (Fig. 4A ) and nitrous oxide (Fig. 4B ) increased grey matter rCBV in practically all of the regions studied. In detail, nitrous oxide increased rCBV in the frontal and parietal grey matter more than did iso¯urane. Right hemisphere occipital rCBV, however, was similarly increased by the two drugs. Both drugs increased striatal rCBV, whereas iso¯urane increased thalamic rCBV more than did nitrous oxide ( Fig. 5A and B) . rMTT Iso¯urane (Fig. 6A ) and nitrous oxide (Fig. 6B) increased grey matter rMTT in most regions. Iso¯urane increased rMTT in the frontal, parietal and occipital grey matter more than did nitrous oxide, which decreased parietal rMTT. In contrast, in the basal ganglia nitrous oxide increased rMTT bilaterally more than did iso¯urane (Fig. 7A and B) .
Discussion
Nitrous oxide increased rCBF, rCBV and rMTT predominantly in supratentorial regions, whereas iso¯urane produced predominantly infratentorial increases. In detail, iso¯urane increased occipital grey matter rCBF, which has also been reported by Reinstrup et al. 15 The concomitant unchanged frontal/parietal grey matter rCBF indicates a reversal of the anterior±posterior gradient in rCBF observed in normal resting-state studies. 16 A similar reversal of the anterior±posterior gradient in rCBF was reported during coma 17 and sleep. 18 Therefore, the iso¯urane-induced reversal of the anterior±posterior gradient in rCBF seen in the present study might well re¯ect an altered level of consciousness.
Like iso¯urane, nitrous oxide increased occipital grey matter rCBF in our volunteers, but no reversal of the anterior±posterior gradient in rCBF was found, as the greatest effect of nitrous oxide on rCBF was found in the Effects of nitrous oxide on CBF and CBV frontal and parietal grey matter regions. A similar increase in frontal rCBF has also been reported for nitrous oxide. 19 It has been proposed that nitrous oxide causes disinhibition of frontal cortical activity, 19 and this may prompt an exaggerated frontal distribution of rCBF, whereas iso¯urane typically causes reversal of the anterior±posterior gradient in rCBF. Without psychological tests, however, it is not possible to establish a relationship between a drug-speci®c pattern of rCBF changes and a drug-speci®c altered level of consciousness in humans.
In the infratentorial regions, iso¯urane increased thalamic and striatal grey matter rCBF more than did nitrous oxide. A similar redistribution of rCBF to subcortical regions during iso¯urane administration was reported in humans 4 15 and animals. 20 Although observed, the increase in rCBF in these regions was clearly less pronounced after nitrous oxide.
Nitrous oxide increased rCBV in frontal and parietal grey matter more but in infratentorial grey matter less than did iso¯urane. These heterogeneous increases in rCBV during administration of nitrous oxide and iso¯urane demonstrate that these drugs are not simple vasodilators like hypercapnia, which causes a more uniform increase in rCBV. 21 To further analyse changes in rCBV and rCBF, we used rMTT. rMTT de®nes the average time needed by a tracer to transit the region of interest.
14 Because rMTT equals the ratio of rCBV to rCBF, any increase in rMTT (e.g. in the present study during nitrous oxide and iso¯urane administration) re¯ects a relatively greater increase in rCBV than in rCBF. Iso¯urane increased supratentorial rMTT more than did nitrous oxide, thereby indicating a greater increase in rCBV than in rCBF. In contrast, the infratentorial increase in rMTT was more pronounced under nitrous oxide. The extent to which drug-speci®c changes in rCBF and rCBV, as seen in the present study, are caused by direct vasodilatation and/or metabolically mediated effects on cerebral haemodynamics awaits further investigation. In this regard, it is a limitation of the present study that, during administration of nitrous oxide and iso¯urane, metabolic data (obtained, for example, by means of phosphate spectroscopy), were not obtainable with the whole-body MR scanner we used (Magnetom Vision).
In conclusion, we have shown that nitrous oxide specifically increases rCBF and rCBV in supratentorial grey matter, whereas iso¯urane speci®cally increases rCBF and rCBV in infratentorial grey matter.
